Corporate Officers
Daniel Junius was promoted to President and Chief Operating Officer of ImmunoGen in July 2008 and became President and Chief Executive Officer of the Company effective January 1, 2009. He joined ImmunoGen as Chief Financial Officer (CFO) and Senior Vice President, Finance in May 2005 and was promoted to Executive Vice President, Finance and CFO in July 2006. Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. (NEBS) from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and CFO of NEBS from 1998 to 2002. Prior to NEBS, he was Vice President and CFO of Nashua Corporation. He joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming CFO in 1996. Mr. Junius holds a Masters in Management from Northwestern University's Kellogg School of Management. |
John M. Lambert joined ImmunoGen as Senior Director of Research in 1987 and was promoted to Vice President, Research and Development in 1994, to Senior Vice President, Pharmaceutical Development in 2000, to Senior Vice President, Research and Development and Chief Scientific Officer in early 2008, and to Executive Vice President, Research and Development and Chief Scientific Officer in July 2008. Prior to his tenure with ImmunoGen, Dr. Lambert was Assistant Professor of Pathology at the Dana-Farber Cancer Institute in Boston, MA. Dr. Lambert received his doctorate in Biochemistry from Cambridge University in England. |
Dr. Morris brings to ImmunoGen nearly twenty years of experience in the development of anticancer compounds, including experience with registration clinical trials, regulatory approvals, pharmacovigilance, and medical affairs support for marketed products. Prior to joining ImmunoGen, he was the executive vice president and chief medical officer at Allos Therapeutics, Inc., where he led the company's clinical development functions including clinical operations, regulatory, and pharmacovigilance. Prior to joining Allos in 2010, Dr. Morris was vice president worldwide clinical research at Cephalon, Inc., where he contributed significantly to the company achieving its first approved oncology drug, Treanda® (bendamustine). Prior to joining Cephalon in 2007, Dr. Morris was with AstraZeneca Pharmaceuticals (formerly Zeneca Pharmaceuticals), serving most recently as vice president, clinical development projects, oncology. Dr. Morris held a number of leadership roles during his more than ten years with AstraZeneca, including managing the clinical development of all late-stage pipeline and marketed oncology products. |
Mr. Perry joined ImmunoGen in January 2009 as Senior Vice President and Chief Financial Officer and was promoted to his current position in March 2011. Before joining ImmunoGen, Mr. Perry was CFO of Elixir Pharmaceuticals, Inc., where he was extensively involved in partnering and fundraising activities. Prior to Elixir, he was CFO of Domantis, Ltd., an antibody-related therapeutics company acquired by GlaxoSmithKline in 2006. Previously, Mr. Perry was Senior Vice President of Finance and CFO at Transkaryotic Therapies, Inc. (TKT) until its acquisition by Shire plc. in 2005. Before joining TKT in 2003, Mr. Perry held positions of increasing responsibility during his five years at PerkinElmer, Inc., rising to Senior Vice President, Finance and Business Development, Life Sciences. Prior to PerkinElmer, Mr. Perry spent the early part of his career at General Electric, joining the company's financial management program in 1982 and departing in 1996 as Vice President and CFO, GE Medical Systems – Europe, after numerous promotions. Mr. Perry earned his Bachelor's degree from Amherst College. |
Since joining ImmunoGen in 2001, Dr. Amphlett has built a team with industry-leading expertise in the many areas critical to transforming a promising research compound into a commercially-manufacturable, approvable product. These include process development, formulation development, characterization and analytical methods for both the individual product components as well as for the complete drug product. For example, his team developed the commercial-scale production processes for trastuzumab emtansine (T-DM1) and SAR3419 for Genentech and Sanofi, respectively. |
Craig Barrows joined ImmunoGen in October 2007 with over twenty years of legal experience – thirteen as chief corporate legal officer – and a strong transactional background. Mr. Barrows was general counsel of M/A-COM, Inc. from 1994 until the company was acquired in 1996, general counsel and secretary of Media 100 Inc. before he joined New England Business Service, Inc. (NEBS) in 1998, and vice president, general counsel and secretary of NEBS until the company was acquired in 2004. Most recently, Mr. Barrows was vice president, general counsel and assistant secretary of Mercury Computer Systems, Inc. Before transitioning to in-house counsel, Mr. Barrows focused on corporate and securities law at Skadden, Arps, Slate, Meagher & Flom. He earned his undergraduate degree at the University of Chicago and his law degree at Fordham University School of Law. |
Dr. Lutz has held positions of increasing responsibility since joining ImmunoGen as a Scientist in 1992. He gained broad responsibility for ImmunoGen’s preclinical development functions with his promotion to Senior Director of Preclinical Development in 2004 and to Executive Director, Preclinical Development in 2007. In early 2010, he gained added responsibility for project management, becoming Executive Director, Drug Development. |
Prior to joining ImmunoGen in November 2008, Dr. O'Leary was Senior Medical Director, Clinical Oncology at Bayer Corporation, where his responsibilities included leading the global clinical development team for a late-stage anticancer agent. Before joining Bayer in 2006, he was Medical Director, Clinical Oncology at Pfizer Inc. While at Pfizer, Dr. O'Leary led early clinical development teams for two anticancer agents and, later, the global clinical development team for a more advanced compound. Prior to joining Pfizer as Associate Medical Director in 2000, Dr. O'Leary held the position of Medical Reviewer, Division of Oncology Drug Products, at the US Food and Drug Administration (FDA) and was the lead reviewer on Taxol(R) (paclitaxel) for adjuvant use in the treatment of breast cancer. Dr. O'Leary completed his post-doctoral training in Internal Medicine at Winthrop University Hospital, his Hematology/Oncology fellowship at New York University Medical Center, and was a Sessions Physician at Bellevue Hospital in the Breast and the Oncology Clinics in New York. He earned his medical degree from the State University of New York - Health Science Center at Brooklyn in 1990. |
Mr. Williams brings to ImmunoGen over twenty years of business development, deal negotiation and technology in- and out-licensing experience. Prior to joining ImmunoGen in August 2009, he was Senior Director of Business Development at Alnylam Pharmaceuticals, Inc., where he played a central role in the successful execution of large out-licensing and alliance transactions with global pharmaceutical companies. His positions prior to joining Alnylam include being Senior Director of Business Development at Millennium Pharmaceuticals, where he led several major alliances and transactions, and Associate Director, Office of Technology Licensing & Industry Sponsored Research, at Harvard Medical School, where he led activities related to commercializing in-house technology innovations. Mr. Williams has a Masters of Science degree in Management Science (accredited MBA) from the Imperial College of Science, Technology & Medicine, University of London, UK, and a Bachelors of Science degree in Biology from the University of Sussex, UK. |
Dr. Wingrove joined ImmunoGen in early 2011 with over twenty years of regulatory and clinical management experience in the healthcare industry. Before joining ImmunoGen, she was the vice president of regulatory and clinical affairs at Histogenics, where her responsibilities included authoring and gaining approval of a SPA for a Phase III trial for a novel biologic and other regulatory responsibilities in the US and Europe. Prior to that, she was the senior director of regulatory and clinical affairs at MediSpectra, where she was responsible for the full spectrum of regulatory support – from start of clinical testing through marketing approval – for a novel cancer diagnostic product. Prior to joining MediSpectra, Dr. Wingrove was at Pfizer-Infusaid for over ten years, during which time she executed the clinical and regulatory programs associated with the company's combination products. She holds a BS in Biochemistry from Brown University and a doctorate in Biochemical Toxicology from the University of Rochester. |
Last updated December 12, 2012
